Shanghai Junshi Biosciences Co., Ltd. (Stock Code: 1877) announced that its total operating income increased by 28.23% year-on-year for the twelve months ended 31 December 2025, reaching 2.50 billion yuan. The operating loss narrowed to 997.89 million yuan, while net loss attributable to owners of the parent fell to 874.39 million yuan from 1.28 billion yuan a year earlier. Total assets rose to 12.39 billion yuan, up 14.91% compared with the beginning of the period, and equity attributable to owners of the parent increased to 6.03 billion yuan.

According to the announcement, domestic sales revenue of Toripalimab Injection (TUOYI®) jumped 37.72% year-on-year. Toripalimab, which has 12 indications approved for marketing in mainland China and is included in the National Reimbursement Drug List, is the only anti-PD-1 monoclonal antibody included for treating renal carcinoma, triple-negative breast cancer, and melanoma. The product has also secured approvals in over 40 countries and regions. The improved performance and reduced losses were primarily attributed to enhanced expense control, greater R&D efficiency, and continued expansion in commercialization. The final audited results will be disclosed in the company’s 2025 annual report.